I used to think complex gut patients were complex because they were biochemically unique. Different genes, different microbes, different exposures, different stories.
Then I started pulling their labs side by side.
Different platforms. Different companies. GI-MAP, Mosaic OAT, Vibrant Wheat Zoomer, Gut Zoomer, shotgun metagenomics, genetic panels, serum panels, DUTCH, NAD⁺ testing. I started laying them out like puzzle pieces — not to diagnose, but to look for a pattern.
The pattern is there. It is not subtle. It repeats across patients who look completely different on the surface. It spans every layer of testing the functional medicine world uses. And once you see it, you cannot unsee it — because it tells you, unambiguously, that chronic gut dysfunction is not a microbial problem. It is a host capacity problem with a microbial readout.
Before I walk you through what the data shows, let me give you the analogy that will make the rest of this article make sense.
Imagine your colon is a city. The cells lining your colon — the colonocytes — are power plants. Their job is to burn a specific fuel (a short-chain fatty acid called butyrate, which your gut bacteria produce from fiber) and use that fuel to power themselves. When those power plants are running, they consume enormous amounts of oxygen in the process — roughly 70% of all the oxygen that diffuses into the colon wall. That oxygen consumption keeps the inside of your colon — the lumen, where the bacteria live — in a low-oxygen state. A healthy colon is essentially anaerobic.
That anaerobic state is not a coincidence. It is the entire habitat your good bacteria need. Faecalibacterium, Akkermansia, Roseburia, the butyrate producers, the bacteria that produce the protective secondary bile acids — these are obligate anaerobes. They die when oxygen rises even slightly. When your colonocyte power plants are working, oxygen gets consumed and these bacteria thrive. When your power plants fail, oxygen leaks into the lumen and these bacteria die off. The bacteria that take their place — E. coli, Klebsiella, Proteobacteria, Prevotella — are facultative anaerobes, which means they don’t care about oxygen. They bloom in a space they shouldn’t have access to. We call this dysbiosis. We call it SIBO. We call it a microbial problem.
It was never a microbial problem. It is a power plant failure. The bacteria are just the weeds that grow when the garden stops being maintained.
This is what the data actually shows. Across every platform. Across every patient. Layer by layer.
Layer 1: The Microbiome Tests Are Reading the Mirror, Not the Cause
Start with what everyone else starts with — the stool test. Here’s what I keep finding:
What the stool test actually measures
A stool test like GI-MAP or a Vibrant Gut Zoomer looks at two things. First, it counts bacteria — which species are present, in what amounts, and whether they’re above or below the reference range that the lab has built up from healthy controls. Second, it measures the products bacteria make — short-chain fatty acids, bile acid metabolites, compounds like ammonia and phenol and TMAO, digestive markers like fecal fat and pancreatic elastase, immune markers like calprotectin and sIgA. In theory, this gives you a snapshot of the ecosystem and how it’s functioning.
In practice, here’s what I keep seeing in patients with chronic gut dysfunction:
Butyrate production capacity — intact. Shotgun sequencing data across cases shows butyrate-producing gene capacity in the 800–1,200 rpkm range in patients whose guts are severely dysfunctional. What this means in plain terms: the microbial machinery to produce butyrate is fully present. The organisms are there. The genes are there. The butyrate is being made. Stool SCFA panels confirm butyrate output in the adequate-to-high range even in symptomatic clients. So butyrate is not the supply problem — which is what everyone assumes.
Facultative anaerobe expansion — dramatic. Prevotella copri at 44% dominance in a single patient. Bacteroides at five times the minimum reference in another. Total sulfate-reducing bacterial activity at 14× expected — without the classic obligate SRBs like Desulfovibrio present — meaning sulfur metabolism is being driven by facultative organisms that shouldn’t be dominant in a healthy anaerobic colon. What this means: the oxygen-tolerant bacteria are winning. Loudly. They are winning because the space has become habitable to them, which only happens when the obligate anaerobes have been pushed out — which only happens when the oxygen gradient has collapsed.
Secondary bile acid-producing guild — collapsed. In case after case, the organisms that convert your primary bile acids into their protective secondary forms (Clostridium scindens and its relatives) are reduced or absent. One case measured 22 rpkm of secondary bile acid production capacity — a fraction of what a healthy colon produces. Bile-tolerant BSH producers (Bacteroides vulgatus, Prevotella, Barnesiella) have expanded into the vacated niche. What this means: one of the most important protective functions of your gut — the conversion of primary bile acids (which are actually toxic at high concentrations) into secondary bile acids (which are protective, antimicrobial, and anti-inflammatory) — has gone offline.
Metabolite profiles — scrambled. Phenols at +647%. Ammonia at +82%. TMA/TMAO at +1,452%. β-glucuronidase at +113%. Indoxyl sulfate paradoxically low. Stool tryptophan depleted. Stool serotonin depleted. GABA depleted. What this means in plain terms: when the healthy fiber-fermenting bacteria are gone, the remaining bacteria do something different. Instead of fermenting fiber to produce butyrate and protective short-chain fatty acids, they ferment protein to produce ammonia and phenols and branched-chain fatty acids — compounds that are toxic to your gut lining, toxic to your liver, and directly inflammatory. The TMA/TMAO elevation tells me that bile-tolerant organisms are also processing dietary choline and carnitine into a compound that is pro-atherogenic (contributes to cardiovascular disease) and inflammatory. These metabolite changes are why patients with chronic gut dysfunction often have elevated inflammatory markers, cardiovascular risk markers, and neurological symptoms in addition to gut symptoms — the same gut bacteria that are producing the wrong things are producing them in quantities the liver and brain also have to deal with.
Every one of these findings is downstream of one thing: the colonic lumen has lost its anaerobic gradient. The garden lost its conditions, and the weeds grew in.
So the real question is not why do these bacteria overgrow? The real question is why did the oxygen gradient collapse?
It collapsed because the colonocyte — the cell whose job is to consume that oxygen through butyrate β-oxidation — stopped being able to do its job.
Which brings us to the mitochondrial data.
Layer 2: The Mitochondrial Data Tells You Exactly Where the Engine Is Failing
What the Organic Acids Test actually measures
The Organic Acids Test (OAT) is a urine test, most commonly run through Mosaic Diagnostics or Great Plains. It measures about 75 different small molecules that your body produces as it burns fuel, builds neurotransmitters, and processes waste. When specific organic acids are elevated or suppressed, they tell you precisely where your metabolism is backed up — which enzymes are struggling, which cofactors are missing, which pathways are blocked.
Most practitioners run the OAT to look for yeast and mold markers. That is the least interesting thing it measures. The OAT is the most direct non-invasive window we have into mitochondrial function — which means it is the most direct window into what is happening inside your gut cells. Here’s what it shows in my patients:
Ethylmalonic acid — elevated. What this is: a small organic acid that accumulates when a mitochondrial enzyme called short-chain acyl-CoA dehydrogenase (SCAD) cannot keep up with its work. What SCAD does: it is the first enzyme in the pathway that burns short-chain fatty acids — including butyrate, which is a 4-carbon fatty acid — for energy. What elevated ethylmalonic acid means: your colonocyte has butyrate sitting there, ready to be burned, but the enzyme that’s supposed to burn it is failing. This is the chemical equivalent of your colonocyte writing you a note that says I have the fuel. I can’t use it.
3-hydroxybutyric acid at 4× reference range. Acetoacetic acid at 4.7× reference range. What these are: ketone bodies. Your liver produces them as a backup fuel when your cells can’t burn glucose efficiently. What this means in a gut patient who isn’t fasting or on a ketogenic diet: your mitochondria have shifted away from normal energy metabolism and are running on backup fuel. In plain terms, your body is running on its reserve gas tank because the main one isn’t delivering. This isn’t a dietary pattern — it’s a mitochondrial failure pattern.
Suberic, adipic, and sebacic acids — elevated. What these are: medium-chain dicarboxylic acids. They appear in urine when fats that were supposed to be completely burned inside the mitochondria got only halfway through the process and leaked back out. What this means: the fatty acid oxidation machinery is jamming. It’s not finishing the job. Fats that should have been converted to clean energy are instead being partially oxidized and excreted as waste.
Quinolinic acid — elevated, often at the upper ceiling of the reference range. What this is: a breakdown product of tryptophan, the amino acid that is supposed to be converted to serotonin. What happens normally: about 95% of the tryptophan in your body goes to serotonin production. What happens under inflammation: an enzyme called IDO1 (indoleamine 2,3-dioxygenase) gets turned on by inflammatory signals and diverts tryptophan away from serotonin and into a different pathway that ends in quinolinic acid. Quinolinic acid is not neutral — it is an NMDA receptor agonist, which means at sustained elevations it is directly neurotoxic. In one case, the quinolinic acid to 5-HIAA ratio was 0.12 (reference 0.32–1.1), meaning tryptophan was being massively shunted away from serotonin production toward neurotoxic kynurenines. Why this matters to a patient: this is the biochemistry behind brain fog, mood dysregulation, sensory hypersensitivity, anxiety, and insomnia in gut patients. It is the same inflammation in the gut expressed in a different tissue. Your brain symptoms are not separate from your gut symptoms. They are the same disease measured in two different places.
Pyroglutamic acid — elevated. What this is: a marker of glutathione depletion. Glutathione is your body’s master antioxidant. What elevated pyroglutamic acid means: your cells are consuming glutathione faster than they can remake it, which tells you oxidative stress is significantly elevated. This happens when mitochondria are leaking reactive oxygen species — which happens when the electron transport chain is impaired — which happens when the fuel the mitochondria need can’t be properly oxidized.
Elevated uracil. What this is: a DNA building block that accumulates when one-carbon metabolism (the folate/B12 cycle) is bottlenecked. What this tells you: the system that converts folate into the form your cells need for DNA synthesis and repair isn’t working well enough. When uracil accumulates, it gets misincorporated into DNA where it shouldn’t be, causing DNA strand breaks. This is one of the most destructive downstream consequences of methylation failure.
Every one of these markers, in every patient I’ve seen, points at the same thing: the mitochondria in the gut wall have lost the capacity to burn the fuel the bacteria are delivering to them.
Why this prevents butyrate oxidation — in plain terms
Let me walk through what’s actually happening at the cellular level, because this is the piece that once it clicks, the entire model clicks:
Bacteria produce butyrate from the fiber you eat. You don’t make butyrate. They do. This works, and it keeps working even in sick patients. Supply is not the problem.
Butyrate has to get into the colonocyte to be useful. It enters through a transporter called SLC5A8, which sits on the cell’s outer membrane. Think of SLC5A8 as the fuel pump on the side of the power plant. Without this transporter working, no butyrate gets inside, regardless of how much is sitting in the lumen.
Butyrate has to get into the mitochondrion. Once inside the colonocyte, it travels into the mitochondrial matrix where it can be burned.
Butyrate has to be oxidized through a specific enzymatic sequence (SCAD → other enzymes → acetyl-CoA → TCA cycle → electron transport chain → ATP). Every single step in this sequence requires specific enzymes, specific cofactors (B vitamins, magnesium, iron, sulfur, NAD⁺, CoQ10), and a properly functioning mitochondrial membrane.
The oxidation produces ATP — the energy the colonocyte needs to live — and consumes oxygen in the process. That oxygen consumption is what keeps your colon anaerobic.
Now stack the data against this sequence:
Elevated ethylmalonic acid → SCAD is struggling → step 4 is broken
Elevated 3-hydroxybutyrate and acetoacetate → mitochondria have shifted to backup fuel → entire pathway is compromised
Elevated suberate and adipate → fatty acids aren’t finishing oxidation → electron transport chain is backed up
Elevated pyroglutamic acid → oxidative stress is high → mitochondrial membranes are being damaged, which worsens every step above
So the data is telling you, in five different ways simultaneously: the colonocyte has the butyrate available, has the transporter (maybe — more on this in the genetics layer), but cannot complete the process of burning it. The engine is choking at every stroke.
And — critically — this is why oral butyrate supplementation often fails. When butyrate accumulates inside a cell but cannot be oxidized, it doesn’t just sit there harmlessly. It starts acting as an HDAC inhibitor, altering gene expression in cells that were never supposed to be experiencing HDAC inhibition outside of a controlled metabolic context. This can cause symptoms that look like supplement intolerance — nausea, flushing, brain fog, fatigue — and it’s why patients with chronic gut dysfunction so often “react badly” to butyrate or fiber. They are not making it up. Their cells genuinely can’t process what you’re giving them.
The microbes are not the bottleneck. The engine is. And the engine is broken at five different points simultaneously — any one of which would be enough to drive the entire downstream cascade.
Layer 3: The Immune Signaling Collapse That Standard Testing Misses
This is the layer most practitioners never get to, because the markers they’re taught to trust don’t see it. It’s also the layer that explains why so many patients with chronic gut dysfunction have been told, repeatedly, that their tests look “normal” while their body is falling apart.
Why calprotectin misses this
Fecal calprotectin is the marker most gastroenterologists lean on to decide whether your gut is “inflamed.” If it’s elevated, you get taken seriously. If it’s normal, you get told it’s functional — which is medical shorthand for we don’t know what’s wrong with you, and we’re going to act like nothing is.
Here’s the thing. Calprotectin measures one type of inflammation only: neutrophil-driven inflammation. Neutrophils are the immune cells that rush to sites of acute infection or IBD-type inflammation. Calprotectin is their signature. When neutrophils are at work, calprotectin goes up. When they’re not, calprotectin stays low.
But neutrophils are not the inflammation that drives chronic gut dysfunction. Mast cells are. Eosinophils are. Innate lymphoid cells (ILC2s) are. Mitochondrial damage signals (DAMPs) are. Sustained low-grade endotoxemia from LPS translocation is. None of these show up on a calprotectin test.
Here’s what I keep finding:
Fecal calprotectin — values of 20, 16, 25 in clients who are visibly, measurably sick. Bloating that doesn’t resolve. Post-meal reactions within 15 minutes. Food reactivity narrowed to a handful of tolerated items. Nerve pain. Skin involvement. Insomnia. And yet calprotectin stays below the IBD threshold, and the GI specialist says their inflammation is fine. It isn’t fine. It’s just not neutrophil-driven — and calprotectin is looking for the wrong kind of inflammation.
sIgA — normal. Another marker that looks fine when the mucosal immune system is failing at a different level. Low sIgA would tell you mucosal defense is weak. Normal sIgA tells you almost nothing about whether mast cells are degranulating, whether eosinophils are infiltrating, whether the local cytokine balance has shifted toward a Th2/Th17 pattern that drives reactivity. None of these show up on standard panels.
Zonulin — elevated. Values around 58 in the same patients whose calprotectin is low. What this means: the tight junctions between your gut cells — the molecular zippers that keep the contents of your gut from leaking into your bloodstream — are loosening. But loosening without neutrophilic inflammation. That combination alone tells you the barrier is failing because of an energy problem, not an infection. The cells don’t have enough ATP to maintain their own structural proteins.
The IAP finding — the most important invisible signal
IAP (Intestinal Alkaline Phosphatase) is an enzyme your colonocytes and enterocytes produce and secrete into the gut lumen. It has one function that matters more than any other: it dephosphorylates LPS (lipopolysaccharide), the toxin found on the outer membrane of gram-negative bacteria.
Here is why this matters enormously. LPS in its fully phosphorylated form is one of the most inflammatory molecules in human biology. It binds a receptor called TLR4 on your immune cells, and triggers a cascade that ends in massive cytokine release, mitochondrial damage, and systemic inflammation. IAP clips off the phosphate groups from LPS, converting it to a monophosphoryl form that is roughly 100 times less inflammatory.
In a healthy gut, IAP is continuously produced and continuously defusing the LPS generated by your normal gut bacteria before it can cause harm. It is one of the quietest, most essential homeostatic systems in your body.
Now watch what happens when IAP fails:
In one of my cases, IAP was measured at zero. Zero. The patient had been through a combination of antibiotics and a viral infection that suppressed IAP transcription. Here is what that means in practical terms: LPS was crossing this patient’s gut wall in its fully toxic form, continuously, every hour of every day.
And here is the cascade that LPS then produced:
LPS binds TLR4 on immune cells and epithelial cells.
TLR4 signals through an intracellular pathway (MyD88 → IRAK → TRAF6 → NF-κB). Think of NF-κB as the master inflammation switch.
NF-κB turns on hundreds of inflammatory genes — including a gene called CD38.
CD38 is the dominant consumer of NAD⁺ in human cells. NAD⁺ is the coenzyme that virtually every mitochondrial enzyme depends on. CD38 consumes it at roughly 100 times the rate that the sirtuins (the deacetylase enzymes that use NAD⁺ to protect your mitochondria) consume it.
NAD⁺ drops.
SIRT1 and SIRT3 — the enzymes that maintain mitochondrial function, suppress inflammation, and regulate circadian metabolism — run out of their cofactor and stop working.
Mitochondrial function degrades further — in the very cells that are supposed to consume oxygen and maintain the anaerobic gut environment.
The colonocyte gets worse at burning butyrate.
The oxygen gradient collapses further.
Dysbiosis deepens.
More LPS gets produced.
More LPS crosses the gut wall (because IAP is still at zero).
The loop closes on itself and locks in place.
This entire cascade produces no elevated CRP (because it’s subacute, not acute), no elevated calprotectin (because it’s not neutrophil-driven), and no sign on the standard tests a gastroenterologist would order. It is the single most important driver of chronic fatigue, brain fog, insulin resistance, neuroinflammation, and progressive metabolic deterioration in this patient population — and it is completely invisible to the testing almost everyone gets.
The only way you see it is if you know what to measure. Serum LBP (lipopolysaccharide binding protein). Whole blood intracellular NAD⁺. Pyroglutamic acid on the OAT. IAP on a comprehensive stool panel. These are not esoteric tests. They are just not ordered, because the people ordering tests don’t know to look at this layer.
Your immune system isn’t quiet. It’s screaming. The tests are just deaf to what it’s screaming about.
Layer 4: The Genetics — A Susceptibility Map, Not a Diagnosis
This is where the field gets it most wrong, in both directions. The conventional side dismisses genetics as irrelevant. The functional side treats a heterozygous MTHFR variant like a death sentence and hands the patient 5-methylfolate supplements as if that’s the answer. Both are wrong.
What genetic testing actually tells you
A genetic panel — whether from 23andMe, AncestryDNA, or a clinical whole genome sequence — gives you the specific variants you inherited at each of thousands of locations in your DNA. Certain variants affect how well specific enzymes work. Some variants reduce enzyme activity by 30%. Some by 70%. Some have no effect at all.
What genetics does not tell you is whether any of this matters for your current symptoms. A variant that reduces an enzyme’s activity by 70% might be fully compensated for by your lifestyle, your diet, and your other pathways. Or it might be the hidden weakness that, when pushed by the right stressor, collapses everything downstream.
Genetics is a susceptibility map. It tells you where the thin ice is. It doesn’t tell you whether you’re currently standing on it.
Here is what the genetic data actually adds when you overlay it on the mitochondrial and immune findings:
MTHFR C677T homozygous (TT) → ~70% reduction in an enzyme called methylenetetrahydrofolate reductase. What this enzyme does: it produces the active form of folate (5-methyl-THF) that your body needs to maintain a substance called SAM (S-adenosylmethionine). Why SAM matters: SAM is the universal methyl donor your cells use for hundreds of reactions — making neurotransmitters, regulating DNA methylation, processing hormones. The key connection to the gut: the enzyme DNMT3A, which methylates DNA to keep gene-silencing patterns in place, uses SAM. When SAM is short, DNMT3A fails. When DNMT3A fails, the epigenetic maintenance of a gene called SLC5A8 — the gene that codes for the colonocyte butyrate transporter we talked about in Layer 2 — collapses. SLC5A8 gets silenced. The colonocyte can no longer import butyrate. The fuel stops reaching the engine. This is the single most important gene-to-disease pathway in chronic gut dysfunction, and almost nobody in the field talks about it.
MTHFR compound heterozygous (C677T + A1298C) → moderate enzyme deficit, but here’s where it gets interesting. In one of my post-infectious cases, this patient had paradoxically elevated serum B6. That looks contradictory — how can someone with methylation issues have high B6? Until you understand the mechanism: pyridoxine (inactive B6) must be phosphorylated to pyridoxal-5-phosphate (the active form) by an enzyme that needs zinc to work. And the active form, PLP, is recycled through the action of alkaline phosphatase — including IAP. When IAP is at zero and zinc is borderline, B6 accumulates in the inactive form while the active form — PLP — is functionally deficient. The patient looks fine on a standard B6 panel and is actually depleted where it counts. This is where single-value thinking fails, and mechanistic integration wins. This one finding alone could send a patient down a completely wrong path if interpreted at face value.
Epigenetic silencing of SLC5A8 — not a SNP in the traditional sense, but a methylation-mediated transcriptional suppression that is well-documented in colorectal cancer research and increasingly recognized in IBD. The genetic susceptibility (DNMT3A polymorphisms, methylation capacity from MTHFR), combined with the metabolic stress (mitochondrial dysfunction → SAM shortage), combined with the inflammatory signal (LPS-TLR4-NF-κB driving a specific epigenetic state), produces an acquired epigenetic lock on SLC5A8 in an otherwise genetically normal patient. Why this is devastating: once SLC5A8 is epigenetically silenced, throwing butyrate at the patient doesn’t work — because there’s no functional transporter to import it. The lock has to be released before supply can be useful.
CD38 expression variants modulate how aggressively CD38 upregulates in response to inflammation. Patients with high-expression CD38 alleles deplete NAD⁺ faster under chronic TLR4 stimulation — which means the same LPS load in two different patients produces completely different NAD⁺ trajectories. This is why some people crash under a moderate inflammatory hit and others sail through the same exposure without issues. It’s not resilience. It’s genetic variance in NAD⁺ consumption rate.
SIRT3 hypomorphic variants reduce the capacity of your mitochondria to maintain themselves. Specifically, SIRT3 deacetylates a key mitochondrial enzyme called IDH2. When SIRT3 isn’t working well, IDH2 becomes hyperacetylated and starts producing 2-hydroxyglutarate instead of its normal product, α-ketoglutarate. And 2-HG is a competitive inhibitor of TET2, the enzyme that does DNA demethylation. So the same mitochondrial failure that reduces SAM production also produces a metabolite that blocks the opposing enzyme. The epigenome loses the ability to adjust in either direction. It locks.
NOS3 T-786C, NQO1 C609T, COMT variants — these don’t cause gut disease on their own, but they determine how much load a given patient can tolerate before their host capacity collapses. A patient with low-capacity NOS3 (reduced eNOS expression) has less vasodilatory buffer — less ability to deliver blood flow where it’s needed under stress. A patient with NQO1 heterozygosity can’t recycle CoQ10 efficiently and must supplement as ubiquinol, not ubiquinone — the wrong form will sit in the bloodstream without reaching mitochondria. A patient with COMT Val/Val (high-activity) clears catecholamines faster and is more vulnerable to sustained sympathetic drive — which matters because vagal tone and motility depend on the balance.
Genetics doesn’t cause the collapse. It determines how hard the load has to push before the collapse happens. A patient with clean genetics can absorb a massive insult and recover. A patient with three or four mild-to-moderate variants stacked in the wrong pathways can collapse under a stress that a different person wouldn’t even notice.
This is why genetics matters but doesn’t answer questions on its own. It has to be integrated with the metabolic data, the immune data, and the microbial data to tell you what’s actually happening.
Layer 5: The Bile Acid–Mitochondrial Axis Closes the Circuit
This is the layer almost nobody in the gut health space is integrating — and it’s one of the most powerful amplifiers of everything above. What the data shows:
Secondary bile acid production — severely reduced. Measured directly at 22 rpkm in one case. Measured indirectly in several others through the microbial signature (dominant bile salt hydrolase producers replacing 7α-dehydroxylators). The bile acid pool has shifted toward primary bile acids and their conjugated forms, and away from the secondary forms (deoxycholic acid and lithocholic acid) that are supposed to dominate a healthy colonic pool.
TMA/TMAO at +1,452% above reference. What this means: bile-tolerant organisms that shouldn’t be dominant are metabolizing dietary choline and carnitine into TMA (trimethylamine), which the liver converts to TMAO. TMAO is directly cardiotoxic, pro-atherogenic, and inflammatory. Why this matters beyond the gut: this is one of the mechanisms linking chronic gut dysfunction to cardiovascular risk, insulin resistance, and kidney strain. Your gut is not a closed system.
Fecal fat 5.4 g/100g (reference <3.5). Fecal sugar 4.3 g/100g (reference <2.5). Malabsorption in the presence of a normal pancreatic elastase (522 µg/g). Why this combination is revealing: the malabsorption isn’t pancreatic — the pancreas is producing plenty of enzymes. So where is the digestion failing? In the micelle formation step, which is bile-acid dependent. Without proper secondary bile acid signaling through FXR (a nuclear receptor that regulates bile acid homeostasis), micelle formation is compromised. Fat doesn’t emulsify. Long-chain fatty acids reach the colon intact, where they feed sulfate-reducing activity and further disrupt barrier function.
Why this poisons the mitochondria — in plain terms
Here is the mechanism that stitches this into the rest of the collapse:
Your liver makes primary bile acids (chenodeoxycholic acid, cholic acid) from cholesterol. These get conjugated to either glycine or taurine, secreted into your small intestine to help digest fat, and then either reabsorbed in the terminal ileum (most of them) or passed through to the colon, where bacteria modify them.
In a healthy colon, specific bacteria (Clostridium scindens and relatives) perform an enzymatic step called 7α-dehydroxylation, converting primary bile acids into secondary bile acids (deoxycholic acid, lithocholic acid). These secondary bile acids are protective, regulatory, antimicrobial, and anti-inflammatory. They are not waste products — they are some of the most important signaling molecules your gut produces.
When the 7α-dehydroxylating bacteria die off — which they do when oxygen leaks into the colon — secondary bile acid production collapses. And here’s where the mitochondrial damage begins:
Primary bile acids accumulate. At elevated concentrations, primary bile acids — especially the deconjugated forms and lithocholic acid when it accumulates — are directly toxic to mitochondrial inner membranes. They insert into the membrane and disrupt its structure.
They uncouple oxidative phosphorylation. The mitochondrial inner membrane is supposed to hold a strict proton gradient that drives ATP production. Bile acid toxicity dissipates that gradient — which means the mitochondria are burning fuel but not producing ATP. Energy that should be stored is lost as heat.
They trigger the mitochondrial permeability transition pore. This is a catastrophic opening in the mitochondrial membrane that, once open, commits the cell to apoptosis (programmed cell death). You lose colonocytes directly.
They generate ROS. Damaged mitochondria leak superoxide, which damages more mitochondria, which leak more ROS. This is the self-reinforcing oxidative damage spiral.
And when taurine-conjugated bile acids dominate — which happens when bile salt hydrolase-producing bacteria are overexpanding — they feed Bilophila wadsworthia, which produces hydrogen sulfide (H₂S) as its primary metabolic output.
H₂S is the single most potent mitochondrial toxin in human biology. It inhibits cytochrome c oxidase (Complex IV) at micromolar concentrations. Why Complex IV matters: it is the terminal step of the electron transport chain — the step at which electrons are transferred to oxygen to make water. When Complex IV is blocked, the entire electron transport chain backs up, reduces its upstream quinone pool, generates electron leak, produces superoxide, and effectively shuts down oxidative phosphorylation. It is like blocking the drain in a sink while the tap is still running.
So now you have a colonocyte being hit from three directions simultaneously:
Starved of fuel because SLC5A8 is silenced and butyrate can’t be imported
Poisoned by bile acids because secondary bile acid production has collapsed and the primary acid pool is toxic
Respiratorily paralyzed by H₂S because Bilophila has expanded on the shifted bile acid pool
Any one of these would impair the cell. All three together — which is what I see in case after case — produce a colonocyte that has almost no capacity to consume oxygen. The anaerobic gradient in the colon collapses. Facultative anaerobes expand. SIBO tests light up. Everyone focuses on the bacteria.
The bacteria are the smoke. The fire is inside the cell.
Layer 6: Motility — How the Collapse Produces the Stasis That Creates the Overgrowth
This is the layer that most patients actually feel, every day, and that most practitioners have never properly explained. Here is the truth about motility dysfunction in chronic gut patients: it is not a separate problem from the host capacity collapse. It is one of its most direct consequences.
What healthy motility requires
Gut motility — the coordinated, rhythmic contractions that move food, bacteria, and waste through your digestive tract — is not a passive process. It is an energy-intensive, tightly coordinated, multi-system operation that depends on every single thing we’ve covered above. Specifically, it requires:
Functional smooth muscle in the gut wall (which needs ATP).
Functional pacemaker cells called interstitial cells of Cajal (ICCs) that generate the electrical rhythm that drives peristalsis.
A functional enteric nervous system (ENS) — the “second brain” of around 500 million neurons embedded in your gut wall — that coordinates contractions.
Proper vagal tone — the parasympathetic signaling from your brain stem that tells your gut to digest and move.
Functional enteroendocrine cells that release signaling molecules like serotonin, GLP-1, motilin, and CCK at the right times.
Proper bile acid signaling through receptors like TGR5, which regulate both motility and gut hormone release.
The migrating motor complex (MMC) — a sweeping contraction pattern that runs through your small intestine during fasting to clear out bacteria and debris.
Now watch what happens when the host capacity collapse we’ve been describing hits this system:
How the collapse destroys motility
Energy failure compromises smooth muscle contraction. Smooth muscle needs continuous ATP to contract and relax properly. When colonocyte and enterocyte mitochondria are failing, the cells next to them — the smooth muscle cells — are also exposed to the same inflammatory and oxidative environment. Their energy production drops. Contractions become weak and disorganized. The gut gets lazy.
Loss of serotonin production disrupts peristalsis. Your enteroendocrine cells produce around 90% of your body’s serotonin. This gut serotonin is the primary trigger for peristalsis — it acts on 5-HT4 receptors to drive the contractions that move contents forward. What the data shows in my patients: stool serotonin depleted. Why? Because serotonin production by enteroendocrine cells is regulated by short-chain fatty acid signaling through receptors called GPR41 and GPR43. When colonocyte function fails and SCFA signaling is disrupted, serotonin production drops — and peristalsis slows. The same failure that drove the dysbiosis also drove the dysmotility. They are not separate problems.
Simultaneously, serotonin can be over-produced in certain conditions — which is just as disruptive. In one case I analyzed, the depletion of Bifidobacterium breve (an organism that acts as a brake on serotonin-producing enterochromaffin cells) combined with low SCFA signaling caused the opposite problem: uninhibited serotonin release after meals, which triggered mast cell activation through 5-HT2A/2B receptors. That patient had a severe post-meal skin reaction every time she ate. The serotonin brake was gone, and her gut was flooding her system with serotonin after every meal.
LPS and H₂S directly damage the enteric nervous system. Sustained LPS-TLR4 activation causes inflammatory neurodegeneration in the enteric neurons themselves. H₂S at elevated concentrations is neurotoxic. Over time, the ENS loses neurons — and specifically loses the specific types of neurons that regulate motility. This is the mechanism behind the slow, creeping dysmotility that progresses over years in chronic patients.
The migrating motor complex fails. The MMC is the sweeping cleansing wave that runs through your small intestine every 90 minutes during fasting — it is the system that clears out residual food and bacteria so they don’t accumulate and ferment where they shouldn’t. The MMC depends on motilin signaling, on vagal tone, on ICC function, and on energy availability. When any of these fail — and in host capacity collapse, all of them are compromised to some degree — the MMC stops running. Bacteria that should have been swept out of the small intestine accumulate there. They ferment the sugars you eat before they can be absorbed. They produce hydrogen, methane, or hydrogen sulfide depending on their species. This is what a positive SIBO breath test is actually measuring.
Let that sink in. A positive SIBO breath test is not diagnosing a bacterial disease. It is measuring the downstream consequence of a multi-system host failure that includes motility breakdown. Killing the bacteria without restoring the MMC guarantees relapse, because the stasis that selected for the overgrowth is still present.
Bile acid signaling through TGR5 collapses. TGR5 is a receptor that secondary bile acids activate on enteroendocrine cells to trigger GLP-1 release, and on smooth muscle to support proper motility. When secondary bile acids are absent (Layer 5), TGR5 signaling drops — which reduces GLP-1 release, contributes to insulin resistance, and removes one of the key drivers of healthy gut motility. This is why some patients with chronic gut dysfunction also develop metabolic problems. Same receptor, same failure.
Vagal tone collapses. Chronic inflammation, mast cell activation, poor sleep, sustained HPA axis dysregulation, and loss of gut-brain vagal signaling all reduce parasympathetic tone. Without vagal activation, the gut doesn’t enter its rest-and-digest mode. Peristalsis weakens. Digestive secretions drop. The entire system becomes under-stimulated in the exact mode it needs to be stimulated to work.
And in some patients, an autoimmune attack finishes the job. Post-infectious IBS is often mediated by antibodies against a bacterial toxin called CdtB that cross-react with a human protein called vinculin, which is expressed in the ICCs — the pacemaker cells of the gut. In patients who have had a food poisoning event (Campylobacter, Salmonella, E. coli), this antibody cross-reactivity can destroy ICCs permanently. The motility deficit that results is real, measurable, and structural. Testing for anti-CdtB and anti-vinculin antibodies is one of the few cases where a motility intervention can be specifically targeted.
Why this matters for patients
The practical consequence of all of this is that when you have chronic gut dysfunction, you are experiencing a motility disorder on top of a metabolic disorder on top of an immune disorder on top of a microbial disorder — but these are not four diseases. They are four expressions of one mechanism.
This is why motility drugs (prokinetics) work temporarily but don’t fix anything long-term. They’re stimulating a system that has lost the energy, the signaling, the neurons, and the structure to respond properly. You get a push. The push fades. The underlying failure continues.
And it’s why the motility symptoms many patients suffer with — bloating that doesn’t resolve, constipation alternating with diarrhea, post-meal heaviness, the feeling that food isn’t moving, gastroparesis-like patterns — only improve when the upstream host capacity is restored. You don’t fix motility by pushing on motility. You fix motility by fixing the cells that support it.
Why It Is Mechanistically Impossible to Fix This at the Bacterial Level
Once you see these six layers stacked, the conclusion becomes unavoidable. Let me walk through why every bacteria-focused intervention has to fail in this patient population:
Antibiotics (rifaximin, Xifaxan, herbals). These reduce the microbial load temporarily. They do nothing to restore IAP. They do nothing to restore SLC5A8 expression. They do not reverse DNMT3A methyl-donor deficits. They do not rebuild secondary bile acid-producing guilds — in fact, they often destroy the remaining 7α-dehydroxylators as collateral damage. They do not restore motility. They do not reduce LPS translocation after the course ends. When the patient stops the antibiotic, the same host environment that selected for dysbiosis the first time selects for it again. Hence the 44% relapse rate on rifaximin in the published data, and the much higher relapse rate in post-antibiotic chronic cases.
Probiotics. These add organisms to a lumen that can no longer support them. Lactic acid bacteria can’t colonize a colon where the oxygen gradient has collapsed. Faecalibacterium and Akkermansia are obligate anaerobes — they die in the lumen that dysbiotic patients present with. The probiotic passes through. Some patients feel worse during the transient exposure because adding live organisms to a permeable, inflamed gut is not benign. Few feel meaningfully better six months later.
Prebiotics. These add substrate to a system whose transporters and oxidative machinery have failed. The microbes may ferment the fiber and produce butyrate — but if SLC5A8 is silenced and SCAD is impaired, that butyrate cannot be used. Even worse, in some cases the unoxidized butyrate acts as an aberrant HDAC inhibitor outside its normal metabolic context, producing symptoms that look like intolerance. This is why so many patients with chronic gut dysfunction “react badly to fiber” or “react badly to oral butyrate.” Their cells can’t process what’s being delivered.
FMT (fecal microbiota transplantation). Transiently effective in some patients, relapse-prone in most. Same mechanism as probiotics — the transplanted community cannot stably colonize a host whose metabolic environment doesn’t support it. The host selects for the community, not the other way around.
Low-FODMAP and elimination diets. Reduce fermentation substrate to a compromised community, which reduces symptoms by reducing the fuel the overgrowths run on. This is symptom management, not repair. The underlying host failure continues. Many patients spend years on increasingly restrictive diets while their gut function deteriorates in the background.
Prokinetics. Stimulate a motility system that has lost its energy, its neurons, and its signaling architecture. The stimulation produces a partial response. The underlying deficit continues.
None of these interventions is wrong in the general sense. They are wrong because they are being applied at the wrong layer of the system. Treating the bacteria in this patient population is the equivalent of repainting a car with no engine. The paint job is fine. The car still doesn’t run.
What Actually Has to Happen
If the mechanism is host capacity collapse, the intervention sequence has to target the host. Not the microbes. Not primarily. The sequence that my data and the mechanism both support:
First, stabilize immune signaling. Restore IAP function — zinc is the essential cofactor, and PPAR-γ activation supports transcription. Reduce LPS-TLR4 drive by supporting barrier integrity and, where appropriate, binding luminal LPS. Modulate CD38 to preserve NAD⁺ (quercetin, apigenin have the strongest evidence) rather than flooding NAD⁺ precursors into a system that will burn them before they reach SIRT3. This is the step that stops the bleeding.
Second, restore mitochondrial bioenergetics. NAD⁺ precursors only after CD38 drive is reduced — otherwise they are consumed before they can be used. Ubiquinol (not ubiquinone) in patients with NQO1 polymorphisms. Riboflavin in its active R5P form to support flavin-dependent dehydrogenases. Alpha-ketoglutarate as a TCA cycle fuel and TET2/KDM4 cofactor that simultaneously supports mitochondrial function and epigenetic flexibility. In select cases, compounds like SS-31 for cardiolipin and urolithin A for mitophagy have mechanism-of-action traction that matches the pathology.
Third, fix the bile acid–mitochondrial axis. Reduce primary bile acid toxicity where indicated. Support the ecological recovery of secondary bile acid producers — not by taking Clostridium scindens as a supplement (it doesn’t work that way), but by restoring the terrain that supports its re-emergence. Manage taurine-conjugate load to reduce Bilophila pressure.
Fourth, restore transporter and epigenetic function. SLC5A8 re-expression is the downstream goal — reached by restoring SAM availability (which requires mitochondrial function), reducing the inflammatory drive that silenced it, and letting DNMT3A regain methyl-donor adequacy. This is not a supplement protocol. It is a system state that emerges when the upstream conditions are restored.
Fifth, let motility recover as the cells and signals come back. Vagal tone exercises, circadian rhythm restoration, proper meal spacing to allow MMC activation, and in selective cases targeted prokinetic support. But as an accelerator, not as the primary lever — because the primary lever is cellular.
Only then: targeted microbial work, if still needed. In most cases, by the time the first five steps are meaningfully in place, the microbial community has reorganized on its own. The oxygen gradient has come back. The obligate anaerobes have reclaimed their niche. The SIBO breath test goes negative without a single dose of rifaximin. The bacteria were the readout of the host state. Fix the host state, and the readout changes.
Mast cell stabilization runs alongside all of this for symptom control — but it is never the fix. It is the airbag. Not the engine.
The Bigger Point
Across genetics, mitochondrial metabolomics, immune markers, bile acid chemistry, motility assessment, and stool sequencing — six different testing layers, twenty-five-plus data points — every finding that keeps appearing in my patient population converges on the same place: the colonocyte, and the immune interface adjacent to it, and the mitochondrial network that powers both, and the entire operational architecture that depends on them.
The microbiome is a downstream readout. The calprotectin is the wrong marker. The serum B6 is misleading. The butyrate production is intact. The motility problem is not a separate problem. The colonocyte has lost the capacity to use any of it.
This is the Host Capacity Model. It is not a theory I am defending. It is a pattern that the data is forcing me to accept. Every client I have worked with has confirmed it. Every piece of research I have reviewed has been consistent with it. Every treatment protocol that has been aimed above the host layer has worked, and every protocol that has been aimed below it has failed.
If any of this recognized you — the decade of relapsing SIBO, the calprotectin that came back “normal” while your gut fell apart, the methylation protocol that didn’t help, the supplement stack that keeps growing, the antimicrobials that worked for six weeks and failed for six years, the prokinetics that gave you a week of relief and then stopped working, the feeling that every specialist is seeing a different piece and nobody is seeing the whole — the conversation starts somewhere different than where you’ve been. It starts at the cell.
I take a limited number of complex, treatment-resistant cases through Biomelogic. If you want to understand whether this framework fits your specific pattern, you can reach me at research@biomelogic.net. Ongoing research and writing are at Substack @mohammedattallah.
The bacteria are not the problem. They never were. They were the reflection. The problem was always the cell that stopped being able to do its job — and until that reframe takes hold, another generation of patients will go through the same cycle that the ones I see every week went through before they found me.
Treat the cause. Or keep treating the consequence. Those are the only two options. The data has made them that clear.
— Mohammed Attallah, Biomelogic